Genes mapping to approved or investigational drugs included CALCRL (target of several medications used to manage migraine disorder), LAMC1 (target of ocriplasmin, used to treat vitreomacular traction), and ANGPTL4 (investigational target for hypertriglyceridemia). The gene discussed is CALCRL; the disease is migraine disorder.